Wall Street analysts expect Kamada Ltd (NASDAQ:KMDA) to post earnings of $0.03 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Kamada’s earnings, with estimates ranging from $0.02 to $0.04. Kamada posted earnings per share of ($0.10) during the same quarter last year, which indicates a positive year over year growth rate of 130%. The firm is scheduled to issue its next earnings results on Tuesday, May 15th.
On average, analysts expect that Kamada will report full-year earnings of $0.21 per share for the current year, with EPS estimates ranging from $0.18 to $0.23. For the next fiscal year, analysts anticipate that the firm will report earnings of $0.48 per share, with EPS estimates ranging from $0.42 to $0.53. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Kamada.
Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.10. The firm had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. Kamada had a net margin of 6.71% and a return on equity of 9.06%.
Shares of Kamada (KMDA) traded up $0.15 during mid-day trading on Tuesday, reaching $5.15. 9,500 shares of the company’s stock were exchanged, compared to its average volume of 30,084. The firm has a market capitalization of $201.31, a PE ratio of 30.30 and a beta of 1.14. The company has a current ratio of 3.30, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Kamada has a 1 year low of $3.75 and a 1 year high of $8.61.
Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. Vanguard Group Inc. lifted its position in shares of Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares in the last quarter. Navellier & Associates Inc acquired a new position in shares of Kamada during the second quarter worth $303,000. Paulson & CO. Inc. lifted its position in shares of Kamada by 8.2% during the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after purchasing an additional 60,000 shares in the last quarter. Worth Venture Partners LLC acquired a new stake in Kamada in the third quarter valued at $246,000. Finally, Analyst IMS Investment Management Services Ltd. raised its holdings in Kamada by 125.5% in the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares in the last quarter. 6.26% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/13/zacks-brokerages-anticipate-kamada-ltd-kmda-to-post-0-03-earnings-per-share.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.